What a large panel can and can’t tell a healthy adult
For deaths, the health-check evidence is rated high certainty1. A lipid panel feeds heart-risk estimates, and a glucose or HbA1c screening test is recommended for asymptomatic, nonpregnant adults 35 to 70 with overweight or obesity26. A European lipid-society consensus says to test Lp(a) at least once, and the US cholesterol guideline backs apoB in selected cases35. Beyond those, extra markers mainly add cost and chances of a false alarm713.
A blood test measures one value on one day. It’s useful when the result feeds a decision that guidelines link to better outcomes, such as whether to start a statin. A long list of results doesn’t, by itself, show that you’ll live longer or healthier.
The closest trial evidence comes from general health checks. These are offers of screening tests and examinations to adults who weren’t selected for any disease or risk factor. A 2019 Cochrane review found 17 randomized trials, 15 of them with outcome data on 251,891 participants1. The reviewers concluded that general health checks are unlikely to be beneficial1.
Health checks had little or no effect on total mortality (risk ratio 1.00, 95% CI 0.97 to 1.03; 11 trials, high-certainty evidence)1. The same held for cancer mortality (1.01, 0.92 to 1.12; 8 trials, high certainty)1. They probably had little or no effect on cardiovascular mortality (1.05, 0.94 to 1.16; 9 trials, moderate certainty)1. Fatal and non-fatal ischemic heart disease showed little or no difference (0.98, 0.94 to 1.03; 4 trials, high certainty)1. Stroke probably showed little or no difference (1.05, 0.95 to 1.17; 3 trials, moderate certainty)1.
These trials are indirect evidence. They tested health checks as a package, not the large panels that longevity services sell now. We found no randomized trial showing that a large consumer blood panel or a biological-age test improves health outcomes compared with usual care.
Which blood tests do guidelines back for healthy adults?
Cholesterol testing has the clearest job. The US Preventive Services Task Force (USPSTF) recommendation concerns prevention in adults without known cardiovascular disease or its signs or symptoms. It does not cover LDL cholesterol above 190 mg/dL or known familial hypercholesterolemia; those groups need different guidance2. Within that scope, the statin recommendation covers adults 40 to 75 with at least one cardiovascular risk factor: dyslipidemia, diabetes, high blood pressure or smoking2. It recommends a statin when their estimated 10-year cardiovascular risk is 10% or more (grade B)2. At 7.5% to under 10%, it recommends offering one selectively (grade C)2. The risk calculator it names, the Pooled Cohort Equations, uses cholesterol levels among its inputs2. For adults 76 and older, the USPSTF found the evidence insufficient to weigh starting a statin2.
Apolipoprotein B (apoB) represents the total concentration of atherogenic (plaque-promoting) lipoprotein particles in the circulation4. The 2018 US cholesterol guideline names triglycerides of 200 mg/dL or more as a relative reason to measure apoB3. It lists an apoB of 130 mg/dL or more as a risk-enhancing factor, a level that corresponds to an LDL cholesterol of 160 mg/dL or more3. It also notes that apoB measurement carries extra expense and may not be reliable in some laboratories3.
The National Lipid Association published an expert consensus statement on apoB in 20244. It says apoB has been shown to be superior to LDL cholesterol for risk assessment, both before and during cholesterol-lowering treatment4. It adds that when LDL cholesterol disagrees with apoB or non-HDL cholesterol, risk generally aligns better with apoB or non-HDL cholesterol4. The statement’s recommendations are based on the available evidence and expert opinion4. We found no trial showing that apoB-guided care improves outcomes compared with care guided by LDL cholesterol.
Lipoprotein(a), or Lp(a), is the main case for a once-only test. A 2022 European Atherosclerosis Society consensus statement recommends testing it at least once in adults5. Levels are more than 90% determined by genes and usually reach adult levels by about age 5, the statement notes5. At the time of the statement, drugs that specifically lower Lp(a) were still in phase II and III trials5. Until they’re available, the statement recommends early, intensive management of other risk factors, targeted to overall cardiovascular risk and the Lp(a) level5.
The US guideline says an Lp(a) of 50 mg/dL or more (125 nmol/L or more) may be considered a risk-enhancing factor3. It names a family history of premature heart disease as a relative reason to measure it3. It also notes that no available randomized trial evidence supports Lp(a) levels as a target of therapy3.
For blood sugar, the USPSTF recommends screening asymptomatic, nonpregnant adults 35 to 70 who have overweight or obesity (grade B)6. The test can be fasting glucose, HbA1c or an oral glucose tolerance test6. After a normal result, it says screening every 3 years may be reasonable6. It adds that a diabetes diagnosis should be confirmed with repeat testing6.
| Test | Who the guidance points to | How often | Source |
|---|---|---|---|
| Standard lipid panel | Adults 40 to 75, as an input to a 10-year cardiovascular risk estimate that guides statin decisions | Not stated in the USPSTF statin statement | USPSTF 20222 |
| Fasting glucose or HbA1c | Adults 35 to 70 with overweight or obesity; the USPSTF says to consider a lower BMI cutoff (23 or more) for Asian American adults | Every 3 years may be reasonable after a normal result | USPSTF 20216 |
| Lp(a) | All adults (European consensus); US guideline names family history of premature heart disease as a relative indication | At least once | EAS 20225; ACC/AHA 20183 |
| apoB | An add-on to the lipid panel; the US guideline names triglycerides of 200 mg/dL or more as a relative indication | No interval stated | ACC/AHA 20183; NLA 20244 |
What it doesn’t show: more markers, more benefit
The USPSTF has reviewed several markers that appear on longevity panels, and each got an I statement for adults without symptoms79. That means the evidence was insufficient to assess the balance of benefits and harms. An I statement isn’t a finding of harm or of no benefit.
For heart risk, the USPSTF found sparse evidence on adding three tests to the Pooled Cohort Equations7. They’re high-sensitivity C-reactive protein (hs-CRP), the ankle-brachial index and a coronary artery calcium score7. For hs-CRP and the ankle-brachial index, a single study of each used the Pooled Cohort Equations7. In those studies, adding either one didn’t improve how well the model separated higher-risk from lower-risk people7.
Across four studies, a calcium score gave a very small to small improvement, but its clinical meaning was largely unknown7. Evidence was inadequate to judge whether treatment decisions guided by any of the three reduce cardiovascular events or deaths7. Until further evidence shows added benefit, the USPSTF advises using the Pooled Cohort Equations to guide treatment decisions7.
For vitamin D, the USPSTF found no studies that directly evaluated the benefits of screening8. In pooled trials that treated low vitamin D levels in adults without symptoms, there was no difference in deaths, fractures or new cases of diabetes8. For thyroid function, it found no studies that directly evaluated the effects of screening on health outcomes9. Nor did it find trials of treating subclinical hypothyroidism that measured final health outcomes9. A May 2024 literature scan found a lack of new evidence to support an updated review9.
None of this means these markers are meaningless. For an adult without symptoms, though, a result on these tests hasn’t been shown to lead to better health. And the extra result can still trigger follow-up testing, as the safety section below explains.
How reliable are biological-age clocks?
Epigenetic clocks estimate age from DNA methylation patterns at selected sites in the genome. They’re an active research tool. But three problems limit what a consumer score can tell you.
Reliability: a 2022 Nature Aging study compared replicate measurements of the same samples for six prominent clocks10. Technical noise alone produced differences of up to 9 years between replicates10. Versions rebuilt from principal components brought most replicates within 1.5 years of each other10. That shows how much the choice of algorithm matters. A single score, or a change between two scores, can fall inside that noise.
Consistency: a study of 964 members of New Zealand’s Dunedin cohort, all born in 1972 and 1973, found low agreement between 11 measures of biological aging11. The measures were telomere length and its rate of erosion, three epigenetic clocks and their rates of change, and three biomarker composites11. One epigenetic clock, built on 71 DNA methylation sites, was consistently related to physical functioning, cognitive decline and subjective signs of aging such as facial appearance11. So were the biomarker composites, though in each case the effect sizes were modest11. Because the measures disagree, you can’t assume a score from one service matches a score from another that uses a different clock.
Validation: a 2024 review in Nature Medicine notes that biomarkers of aging could serve as surrogate endpoints for evaluating interventions aimed at healthy aging12. But it says no consensus exists on how they should be validated before they move into the clinic12. The journal’s summary of the review calls rigorous validation critical to their clinical translation12. We found no trial showing that lowering a clock score by any means reduces disease or death.
Safety: false positives, incidental findings and care cascades
Most laboratory reference ranges are set at the central 95% of results from healthy people13. So by design, about 5% of healthy people fall outside the range on any one test13. A 2025 family-medicine review calculates that across a panel of 20 tests, 64.2% of healthy people would have at least one result flagged as abnormal13. That calculation treats each test as independent, so the exact figure varies. The direction is clear, though: longer panels flag more healthy people.
Some markers are especially prone to misleading single results. The USPSTF notes that TSH can vary by as much as 50% of mean values from day to day, and that false-positive TSH results are common9. About 37% of people with subclinical hypothyroidism return to normal without treatment after several years9. The USPSTF stresses not relying on a single TSH value to establish a diagnosis9. Vitamin D results vary by testing method, and between laboratories using the same method8. The USPSTF notes that misclassification may lead to unnecessary treatment of people who aren’t deficient8.
An unexpected result can lead to repeat tests, imaging, specialist visits and sometimes procedures. The Cochrane reviewers noted that screening increases the use of diagnostic and therapeutic interventions, which can be harmful as well as beneficial1. For thyroid screening, the USPSTF describes overdiagnosis as a concern because it leads to the psychological consequences of labeling and to unnecessary treatment9.
If a service adds imaging, the same problem grows. For coronary calcium scoring, the USPSTF reported that the prevalence of incidental findings on the CT scan ranged from 8% to 58%7. False-positive results can lead to invasive diagnostic procedures such as coronary angiography7. And the ultimate outcomes of follow-up procedures for incidental findings aren’t known7.
What to look for in a testing service
In the US, laboratory testing on people for health assessment, or to diagnose, prevent or treat disease, falls under the Clinical Laboratory Improvement Amendments (CLIA)14. The Centers for Medicare & Medicaid Services (CMS) regulates it, covering about 320,000 laboratory entities14. You can check a laboratory’s certification and survey status with CMS’s free QCOR CLIA Laboratory Lookup14. Certification is about how the laboratory operates. It doesn’t show that a given marker is worth testing in a healthy adult.
Not every company that handles health data is covered by HIPAA. The Federal Trade Commission’s Health Breach Notification Rule applies to vendors of personal health records and related entities that HIPAA doesn’t cover, which can include health apps15. The FTC says a breach isn’t limited to hacking15. Sharing covered health information without the person’s authorization, such as with an ad network, can count15. Check whether a service’s privacy policy allows sharing results with marketers or research partners, and whether you can delete your data and stored samples.
Cost per useful marker is a practical way to compare offers. Divide the price by the number of markers on the panel that a current guideline links to a decision for someone of your age and risk profile. Examples are the lipid panel, Lp(a) once and, where the USPSTF criteria apply, glucose or HbA1c. A large panel with a low price per marker can still cost more per useful result than a basic panel ordered through a primary-care clinician.
- A CLIA-certified laboratory that the service names
- A licensed clinician who reviews your results
- A clear plan for what happens after an abnormal result, including repeat testing
- A privacy policy that says who can see, sell or share your results and whether you can delete them
- A price you can compare per guideline-backed marker, not per marker
- Biological-age scores presented as research estimates, with the clock, tissue and laboratory method named
Sources
- General health checks in adults for reducing morbidity and mortality from disease Cochrane Database of Systematic Reviews, 2019 · systematic review
- Statin use for the primary prevention of cardiovascular disease in adults: preventive medication US Preventive Services Task Force, 2022 · guideline
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol Circulation (American Heart Association and American College of Cardiology), 2018 · guideline
- Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the National Lipid Association Journal of Clinical Lipidology, 2024 · guideline
- Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement European Heart Journal, 2022 · guideline
- Prediabetes and type 2 diabetes: screening US Preventive Services Task Force, 2021 · guideline
- Cardiovascular disease: risk assessment with nontraditional risk factors US Preventive Services Task Force, 2018 · guideline
- Vitamin D deficiency in adults: screening US Preventive Services Task Force, 2021 · guideline
- Thyroid dysfunction: screening US Preventive Services Task Force, 2015 · guideline
- A computational solution for bolstering reliability of epigenetic clocks: implications for clinical trials and longitudinal tracking Nature Aging, 2022
- Eleven telomere, epigenetic clock, and biomarker-composite quantifications of biological aging: do they measure the same thing? American Journal of Epidemiology, 2018 · cohort study
- Validation of biomarkers of aging Nature Medicine, 2024
- Interpretating normal values and reference ranges for laboratory tests Journal of the American Board of Family Medicine, 2025
- Clinical Laboratory Improvement Amendments (CLIA) Centers for Medicare & Medicaid Services · regulator
- Complying with FTC's Health Breach Notification Rule Federal Trade Commission · regulator
How this was written. Written from the sources listed above, checked . It is general information, not medical advice. Talk to a clinician before acting on anything here if you have a health condition or take medication.
Our editorial policy →